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IntrOductIOn
Streptococcus pneumoniae (S. pneumoniae) is one of the gram 
positive diplococcus bacteria, that normally is natural flora of upper 
respiratory system [1]. S. pneumoniae is one of the most common 
reasons for bacterial pneumonia, considered as the main cause of 
meningitis [2] and otitis media as well [3].  
Classifications of serotypes recognized so far are based on genetic 
differences of their polysaccharide capsule. Serotypes of 4, 9V,18C, 
19F, 23F, and 6B are the most important causes of invasive 
pneumococcal infections during childhood [4]. Among children with 
new pneumococcal serotypes, the disease in 15% of cases is likely 
to occur within one month after the microorganism enters the body. 
Pneumococcal infections occurring due to different serotypes are 
more widespread in autumn, and more frequently observed among 
infants, young adults, and elders [5].
In a study, six serotypes of e (1, 19A, 15C, 9V, 11A, and 19F) 
were found in Zahedan, Iran [6]. Colonization of S. pneumoniae 
in nasopharynx was also analysed, discovering that 40-50% of 
8-week-old infants were carriers of S. pneumoniae and as the 
infants grew, acquired pneumonia increased among them [7]. 
Also among S. pneumoniae serotypes isolated from nasopharynx 
of the carrier children, the six serotypes of 23f, 19f, 6b, 14, 6a, 
and 3 were more widespread [8]. The heptavalent S. pneumoniae 
protein conjugate vaccine (PCV7) has polysaccharide conjugates of 
serotypes 4, 6B, 9V, 14, 18C, 19F and 23F. PCV7 was licensed for 
use in the United States in February 2000 and then added to the 
childhood immunization schedule in 2000 [9]. In a study in the USA, 
the incidence of invasive pneumococcal disease (IPD) decreased 
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ABStrAct
Background: Heptavalent pneumococcal vaccine which 
included pneumococcal serotypes 4, 6B, 9V,14, 18C, 19F and 
23F has been regularly used and is effective on preventing 
invasive pneumococcal infection. This study aimed to determine 
vaccine-related serotype distribution in nasopharyngeal carrier 
and healthy children under five years old. 
Materials and Methods: In this cross-sectional study from 
September 2010 to September 2011, 363 nasopharyngeal 
specimens were collected from healthy children in day care 
centers. In positive cultures of streptococcus pneumoniae 
(S. pneumonia) distribution, serotypes were detected by 
Multiplex polymerase chain reaction (PCR). Electrophoresis 
of PCR products was used for detection of serotypes of S. 
pneumoniae.
results: The carrier rate of S. pneumoniae was 29.5% with 95% 
confidence interval as 24.8- 34.5%. Electrophoresis of PCR 
products for detection of serotypes of S. pneumonia revealed 
430, 220, 753, 189, 573, 304, and 384 bp (s) for 4, 6B, 9V, 14, 
18C, 19F, and 23F serotypes of S. pneumoniae, respectively. 
The frequency of 23F, 6B, 19F, and 18C serotypes were 43%, 
34%, 18%, and 5% respectively, but other serotypes (4, 9V and 
14) were not detected. 
conclusion: Based on the 30% carrier rate and high 
prevalence of most of heptavalent pneumococcal conjugate 
vaccine serotypes in our study, this vaccine should be used for 
prevention of invasive infection in Iranian children.
AbolfAzl KhoShdel1, RezA ImAnI RAStAbI2, AbbAS dooStI3, ShAhIn ASKARI4, mASoud hAfIzI5
by 27% after the introduction of the PCV7 [10]. In another study 
a reduction was observed in pneumococcal meningitis cases in 
children under 16 within a 4 y period after universal pneumococcal 
conjugate vaccination in infancy [11]. 
Regarding that the rate of incidence and mortality due to infection 
with these bacteria is growing in children and the potential bacteria 
resistance to antibiotics.
Aim: The main purpose of the present study was to investigate the 
prevalence of various pneumococcal serotypes in PCV7 in children 
under five years according to Multiplex-PCR. 
MAterIAlS And MethOdS
This cross-sectional study was conducted in Cellular and Molecular 
Research Center of Shahrekord University of Medical Sciences, 
Shahrekord, Iran from September 2010 to September 2011 and 
approved by Research Ethics Committee of the University. In the 
present study, 372 children less than five years referred to the health 
care centers in Shahrekord, Chaharmahal and Bakhtiari (southwest 
Iran) were enrolled. All parents of the patients included in this 
project signed informed consent form. The information regarding 
the demographic data, result of throat culture, and serotypes were 
recorded.
Assuming 21% prevalence of carrier rate in the population, 
confidence interval of 95%, and relative error of 20%, the sample 
size was determined as 362 patients. For a more precision the 
sample size was raised to 372 children.  A two stage sampling 
method was used, in the first stage 26 day care centers were chosen 
by simple random sampling and in the second stage, 15 children 
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Primer Sequences Accession
number 
(Genbank)
Amp-
licon 
size 
(bp)
S.pne4-F
S.pne4-R
5’-CTGTTACTTGTTCTGGACTCTCGATAATTGG-3’
5’-GCCCACTCCTGTTAAAATCCTACCCGCATTG-3’
AF316639 430
S.pne6B-F
S.pne6B-R
5’-CGACGTAACAAAGAACTAGGTGCTGAAAC-3’
5’-AAGTATATAACCACGCTGTAAAACTCTGAC-3’
AF316640 220
S.pne9V-F
S.pne9V-R
5’-CTTCGTTAGTTAAAATTCTAAATTTTTCTAAG-3’
5’-GTCCCAATACCAGTCCTTGCAACACAAG-3’
AF402095 753
S.pne14-F
S.pne14-R
5’-GAAATGTTACTTGGCGCAGGTGTCAGAATT-3’
5’-GCCAATACTTCTTAGTCTCTCAGATGAAT-3’
X85787 189
S.pne18C-F
S.pne18C-R
5’-CTTAATAGCTCTCATTATTCTTTTTTTAAGCC -3’
5’-TTATCTGTAAACCATATCAGCATCTGAAAC-3’
AF316642 573
S.pne19F-F
S.pne19F-R
5’-GTTAAGATTGCTGATCGATTAATTGATATCC-3’
5’-GTAATATGTCTTTAGGGCGTTTATGGCGATAG-3’
U09239 304
S.pne23F-F
S.pne23F-R
5’-GTAACAGTTGCTGTAGAGGGAATTGGCTTTTC-3’
5’-CACAACACCTAACACTCGATGGCTATATGATTC-3’ 
AF057294 384
Variable frequency Percent
Gender Girl 191 52.6
Boy 172 47.4
Smoking among 
family members
Yes 53 14.6
No 310 85.4
Antibiotic taking Yes 220 60.6
No 143 39.4
Hospitalization Yes 30 8.3
No 333 91.7
Otitis media Yes 53 14.6
No 310 85.4
Adenoidectomy Yes 35 9.6
No 328 90.4
Serotype Size (bp(s)) number Percent
23F 384 16 43
6B 220 13 34
19F 304 7 18
18C 573 2 5
Total - 38 100
Serotype Percent
23F, 6B, 19F, and 18C 2.7
19F and 18C 2.7
23F and 6B 21
23F, 6B, and 19F 13
6B and 19F 2.7
[table/Fig-1]: Primers used for identification of Streptococcus pneumoniae 
serotype
[table/Fig-2]: Some characteristics of the cases under the study
[table/Fig-3]: Frequency of different serotypes of Streptococcus pneumonia that 
detected from electrophoresis
[table/Fig-4]: Frequency of different serotypes of Streptococcus pneumonia that 
detected from positive culture
were selected from each center by convenience sampling. Healthy 
children under five years were enrolled in this study. Children with 
respiratory tract infection, otitis media, chronic disease or children 
who had received antibiotic within two weeks prior to entering into 
study were excluded. 
The samples were obtained from nasopharyngeal secretion of 
these patients and specimens were streaked cultured on blood and 
chocolate agar plates. All media were overnight incubated for 18h 
to 24h at 35°C under 5% to 8% CO2.
On blood agar, colonies of differentiating S. pneumoniae produced 
a zone of alpha (green pigment) hemolysis. These colonies were 
streaked cultured again on blood agar and a filter paper disk, 
impregnated with Optochin, were placed in the streaked area. An 
inhibition zone of 14 mm or more around a 6-mm disk was used 
for identification of the viridance group streptococcus (VGS) and 
S. pneumoniae. If the inhibition zone was less than 14 mm, bile 
solubility or serology tests would be used for identification of S. 
pneumoniae.
dnA extrActIOn
Bacterial DNA was extracted from each colonies using DNPTM Kit 
(Cinna Gen, Iran) according to the manufacturer’s recommendation. 
The isolated DNA was quantified by spectrophotometric 
measurement at 260 nm wavelength according to the method 
described by Sambrook and Russell [12]. The extracted DNA of 
each sample was kept frozen at -20°C until used.  
MultIplex pcr ASSAy 
In the present study, Multiplex PCR technique was used for 
investigation of serotypes of S. pneumoniae. Also, the oligonucleotide 
primers described by Jourdain et al., and Brito et al., were used 
in this study. The sequences of primers [13,14] for amplification of 
serotypes of S. pneumonia are given in [Table/Fig-1]. 
S. pneumoniae ATCC strain 33400 was used as a positive control. 
A negative-DNA control was performed by adding 1 μL of sterile 
ultrapure deionized water. For investigation of S. pneumoniae 
serotypes, the samples were amplified in a Gradient Palm Cycler 
(Corbett Research, Australia) and Multiplex PCR reaction was 
performed in a total volume of 25 μL in 0.5 ml tubes containing 1 μg 
of genomic DNA, 1 μM of each primers, 2 mM Mgcl2, 200 μMdNTP, 
2.5 μL of 10X PCR buffer, and 1 unit of Taq DNA polymerase 
(Roche applied science, Germany). PCR cycles consisted of an 
initial denaturation step (95°C for 5 min) followed by 30 amplification 
cycles (Denaturation at 94°C for 1 min, annealing at 65°C for 1 min, 
and elongation at 72°C for 1 min) with a final elongation at 72°C for 
5 min,and amplified samples were holed at 4°C.
AnAlySIS OF MultIplex pcr prOductS
The amplified products were detected in 1% agarose gel 
electrophoresis. The electrode buffer was TBE (Tris-base 10.8 g 89 
mM, Boric acid 5.5 g, 2 mM EDTA (pH 8.0), 4 ml of 0.5 M EDTA (pH 
8.0) concentration), combined all components in sufficient H2O and 
stir to dissolve. Aliquots of 10 μL of PCR products were applied to 
the gel. Constant voltage of 80 V for 30 min was used for products 
separation. The DNA fragment size was compared with a standard 
molecular weight (100 bp DNA ladder of Fermentas, Germany). 
[table/Fig-5]: Line M: 100 bp DNA ladder (Fermentas, Germany), lines 1-5 represent 
6B, 18C, 19F, and 23F serotypes of S. pneumoniae and negative control without 
DNA, respectively, in Gel electrophoresis of multiplex PCR for detection of serotypes 
of S. pneumoniae isolated from nasopharyngeal of patients
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After electrophoresis, the amplicons were visualized with ultraviolet 
light after Ethidium bromide (5 μg.mL–1) staining and photographs 
were obtained in gel documentation systems. 
StAtIStIcAl AnAlySIS
The prevalence rates were calculated and analysed using the chi-
square and t-test by SPSS.  P-values less than 0.05 were considered 
statistically significant.
reSultS
This research aims to determine vaccine-related serotype distribution 
in nasopharyngeal carrier and healthy children less than five years.
Three hundred seventy two specimens were totally taken. Nine 
specimens of the participants older than five years old were 
excluded to ensure that all specimens are under five years. Some 
characteristics of the cases have been summarized in [Table/
Fig-2].
Overall, 107 samples were positive, so the rate of pneumococcal 
carriers obtained as 29.5% with 95% confidence interval as 24.8-
34.5%. 
Carriers were largely 4-5 y old and the mean age of the participants 
with positive and negative culture was 4.23±0.84 and 4.29±0.95 y 
respectively (range: 0-5). No significant relationship was observed 
among prevalence of pneumococcal carriers, age and gender 
(p>0.05). 
The pneumococcal prevalence was 30.9% in girls and 27.9% in 
boys, and no significant difference was seen between prevalence of 
pneumococcal carriers and gender (p>0.05).
Electrophoresis of PCR products and positive cultures for detection 
of serotypes of S. pneumonia have been shown in [Table/Fig-3-5].
dIScuSSIOn
For effective control of invasive pneumococcal infection, the 
composition of vaccine must match the prevalence of serotypes at 
local regions. In this study the prevalence of different serotypes of 
these bacteria in the children under the age of five was analysed. 
It has been already proved that this incidence is more prevalent 
among this age group. The findings of this study are consistent with 
those of studies done in other countries; as children get older, the 
acquisition of these bacteria increases [8]. 
In this study, four various serotypes of S. pneumoniae bacteria 
including 23F, 6B, 19F, and 18C using Multiplex-PCR with prevalence 
of each serotype reported as 43%, 34%, 18%, and 5% respectively 
were isolated and other serotypes of these bacteria were not found; 
while in a study in Zahedan, Iran six serotypes of 19F, 1, 19A, 15C, 
9V, and 11A were the most common ones [15].
In Taiwan, six serotypes of 23F, 19F, 6B, 14, 6A, and 3 in comparison 
to  other serotypes were more common [9], that  is consistent with 
the discovered serotypes in the present study. 
In a study carried out in Brazil on the meningitis patients varying 
one month old to 85 y old, serotypes of 5, 23F, 18C, 10A, 6B, 6A, 
7F, 3, 19F, 14, and 34 were found [16].
Besides, in the present study no meaningful difference was 
observed between the increase of Streptococcus carriers, age, sex, 
the number of family members, and state of being smoker, history 
of hospitalization during the last 6 mnth, history of otitis media 
during the last 6 mnth, history of suffering from adenoidectomy, and 
consumption of antibiotic. It is assumed that there is no relationship 
between these parameters and pneumococcal carrier. 
The occurrence of IPD and pneumococcal meningitis in children 
under 2-year-old was respectively 2 and 10 times higher compared to 
the general population, highlighting the importance of pneumococcal 
vaccination in children [17]. PCV7 vaccine was introduced by FDA in 
2000 [9,18]. In the year after the introduction of PCV7, the  Centers for 
Disease Control and Prevention Active Bacterial Core sites reported 
a 69% decrease in the rate of IPD for 0- to 24-month children [19]. 
PCV7 has an efficacy of 94% against IPD due to serotypes included 
in the vaccine and 89% against any IPD, regardless of serotype, 
in a large pre-licensure clinical trial in California [20]. Since PCV7 
introduction, the most common IPD isolates in Belgium, France, 
Germany, Greece, Norway, Portugal, Spain, and the UK were 
serotypes 1, 19A, 3, 6A, and 7F [21]. Infant PCV7 vaccination in 
Germany caused a decrease in pneumococcal meningitis similar to 
what happened in England and Wales [11]. In the USA, introduction 
of PCV7 was followed by a 27% reduction in IPD among under 18 
years and a 35% reduction among children under 2-year-old [15]. 
For PCV7 and other PCV13, the safety efficacy and effectiveness 
have been, in practice, established in different settings [22,23]. 13-
valent pneumococcal conjugate vaccine includes capsular antigens 
of serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 
23F [24]. The implementation of the 13-valent pneumococcal 
conjugate vaccine for children under 2-year-old in Argentina could 
be an effective strategy to be implemented in other countries for the 
decrease in invasive disease [25] and nasopharyngeal carriage of 
S. pneumonia [26]. In a study, 82.2% of S. pneumoniae serotypes 
were included in the 13-valent pneumococcal conjugate vaccine in 
children of 48.3 month age [27]. 
In our country heptavalent vaccination against S. pneumonia 
bacteria has not yet been implemented while most carriers of 
serotypes under study (23F, 6B, 19F, 18C) were discovered in 
heptavalent vaccine.
Based on the studies done, heptavalent vaccination against S. 
pneumoniae bacteria has not yet been implemented in our country 
while most carriers of serotypes under study (23F, 6B, 19F, 18C) 
were discovered in heptavalent vaccine. 
cOncluSIOn
In addition, regarding to high statistics of pneumonic carriers 
(relatively 30% in children under the age of five) in Shahrekord 
region, attributable to coldness of weather and lack of vaccination, 
the necessity of use of this vaccine seems inevitable. Based on 
the findings of the present study, it could be concluded that since 
Streptococcus pneumonia is pathogenic in children, PCV-7 should 
be also administered for children under five years old in Iran. This 
vaccine can be made based on the discovered serotypes. Further 
research on unconsidered serotypes is required. 
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